BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) Institutional Ownership Changes & 13F Activity
BRIDGEBIO ONCOLOGY THERAPEUT (BBOT). Institutional ownership data tracks hedge funds, asset managers, and other institutional investors based on recent SEC Form 13F filings (Q4 2025). This page analyzes institutional buying and selling activity, new holdings, and sold-out positions in the latest reporting period. Notable filers include Cormorant Asset Management, Lp, Deerfield Management Company, L.P., Omega Fund Management, Llc, Wellington Management Group Llp, and Ecor1 Capital, Llc.
| Institution | Type | Change in shares | Change Position % | Shares | Reported stock balance | Portfolio quarter | Filing date |
|---|---|---|---|---|---|---|---|
| Ikarian Capital, Llc | Buy | +220,231 | — | 220,231 | $2.76M | Q4 2025 | Feb 18, 2026 |
| Cormorant Asset Management, Lp | Buy | +17,878,594 | — | 17,878,594 | $223.84M | Q4 2025 | Feb 17, 2026 |
| Deerfield Management Company, L.P. | Buy | +4,885,446 | — | 4,885,446 | $61.17M | Q4 2025 | Feb 17, 2026 |
| Omega Fund Management, Llc | Buy | +3,289,661 | — | 3,289,661 | $41.19M | Q4 2025 | Feb 17, 2026 |
| Wellington Management Group Llp | Buy | +2,907,003 | — | 2,907,003 | $36.40M | Q4 2025 | Feb 17, 2026 |
| Ecor1 Capital, Llc | Buy | +2,823,126 | — | 2,823,126 | $35.35M | Q4 2025 | Feb 17, 2026 |
| Enavate Sciences Gp, Llc | Buy | +2,626,946 | — | 2,626,946 | $32.89M | Q4 2025 | Feb 17, 2026 |
| Citadel Advisors Llc | Buy | +2,530,324 | — | 2,530,324 | $31.68M | Q4 2025 | Feb 17, 2026 |
| Paradigm Biocapital Advisors Lp | Buy | +2,261,749 | — | 2,261,749 | $28.32M | Q4 2025 | Feb 17, 2026 |
| Novo Holdings A/S | Buy | +1,961,317 | — | 1,961,317 | $24.56M | Q4 2025 | Feb 17, 2026 |
| Adage Capital Partners Gp, L.L.C. | Buy | +1,400,000 | — | 1,400,000 | $17.53M | Q4 2025 | Feb 17, 2026 |
| Octagon Capital Advisors Lp | Buy | +1,043,110 | — | 1,043,110 | $13.06M | Q4 2025 | Feb 17, 2026 |
| Armistice Capital, Llc | Buy | +1,000,000 | — | 1,000,000 | $12.52M | Q4 2025 | Feb 17, 2026 |
| Price T Rowe Associates Inc | Buy | +803,134 | — | 803,134 | $10.06M | Q4 2025 | Feb 17, 2026 |
| Casdin Capital, Llc | Buy | +282,312 | — | 282,312 | $3.53M | Q4 2025 | Feb 17, 2026 |
| Millennium Management Llc | Buy | +241,415 | — | 241,415 | $3.02M | Q4 2025 | Feb 17, 2026 |
| Fmr Llc | Buy | +240,300 | — | 240,300 | $3.01M | Q4 2025 | Feb 17, 2026 |
| Highvista Strategies Llc | Buy | +229,263 | — | 229,263 | $2.87M | Q4 2025 | Feb 17, 2026 |
| Adar1 Capital Management, Llc | Buy | +226,248 | — | 226,248 | $2.83M | Q4 2025 | Feb 17, 2026 |
| Sio Capital Management, Llc | Buy | +130,628 | — | 130,628 | $1.64M | Q4 2025 | Feb 17, 2026 |
| Woodline Partners Lp | Buy | +103,707 | — | 103,707 | $1.30M | Q4 2025 | Feb 17, 2026 |
| Moore Capital Management, Lp | Buy | +100,000 | — | 100,000 | $1.25M | Q4 2025 | Feb 17, 2026 |
| Stempoint Capital Lp | Buy | +86,517 | — | 86,517 | $1.08M | Q4 2025 | Feb 17, 2026 |
| Boothbay Fund Management, Llc | Buy | +67,034 | — | 67,034 | $839.27K | Q4 2025 | Feb 17, 2026 |
| Northern Trust Corp | Buy | +58,034 | — | 58,034 | $726.59K | Q4 2025 | Feb 17, 2026 |
| Qube Research & Technologies Ltd | Buy | +35,952 | — | 35,952 | $450.12K | Q4 2025 | Feb 17, 2026 |
| Xtx Topco Ltd | Buy | +28,633 | — | 28,633 | $358.49K | Q4 2025 | Feb 17, 2026 |
| Point72 Asset Management, L.P. | Buy | +23,584 | — | 23,584 | $295.27K | Q4 2025 | Feb 17, 2026 |
| Quadrature Capital Ltd | Buy | +12,922 | — | 12,922 | $161.78K | Q4 2025 | Feb 17, 2026 |
| Persistent Asset Partners Ltd | Buy | +8,585 | — | 8,585 | $107.48K | Q4 2025 | Feb 17, 2026 |
Frequently asked questions about BBOT activity
Which institutional owners are buying BBOT?
Institutional owners buying BBOT include investors who have either initiated new positions or increased their existing holdings based on recent SEC 13F filings. The activity table above highlights which funds added shares in the latest reporting periods and how their positions changed over time.
What does "buy" mean in BBOT activity?
"Buy" means an investor increased their reported position in BBOT compared to the prior reporting period. This reflects growing exposure to BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) rather than necessarily a brand-new position (though new positions also appear as buys when prior quantity was zero).
Is institutional interest in BBOT increasing?
Institutional interest in BBOT can be assessed by comparing the number of tracked funds adding or increasing positions versus those trimming or exiting across the periods shown. A higher number of additions typically signals increasing participation among large filers, but it should be read alongside position sizes and the full table.
Related BBOT Institutional Insights
- BBOT Overview
- BBOT 13F Institutional Holders
- BBOT Superinvestors
- Healthcare Sector Institutional Ownership
- Healthcare Sector Portfolio Overlap
- Institutional Portfolio Overlap & Shared Holdings
- Most Bought Healthcare Stocks By Institutional Investors
- Most Sold Healthcare Stocks By Institutional Investors
- BBOT Insider Trading & SEC Form 4 Activity
- BBOT Articles
- Top Institutional Investor Stock Rankings